Opus Genetics Shares Rise Ahead of Upcoming Trial Data Release
Shares of Opus Genetics (NASDAQ:IRD) rose by 5.9% in pre-market trading ahead of the release of three-month topline data from Cohort 1 of its OPGx-BEST1 Phase 1/2 clinical trial on September 1, 2026. The therapy is being tested for Best Vitelliform Macular Dystrophy and Autosomal-Recessive Bestrophinopathy—two inherited retinal diseases. Analysts at BTIG, B. Riley, and Cantor Fitzgerald have highlighted the importance of this data release as a potential milestone in Opus Genetics' development pipeline. In addition to OPGx-BEST1, Opus completed enrollment for its Phase 3 trial of another gene therapy candidate, OPGx-LCA5, earlier that month. The company's share price increase occurred amid broader declines across U.S. equity indices due to geopolitical tensions and shifting monetary policy expectations.
